Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 35
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
N Engl J Med ; 340(19): 1455-61, 1999 May 13.
Artículo en Inglés | MEDLINE | ID: mdl-10320383

RESUMEN

BACKGROUND: Ductal carcinoma in situ is a non-invasive carcinoma that is unlikely to recur if completely excised. Margin width, the distance between the boundary of the lesion and the edge of the excised specimen, may be an important determinant of local recurrence. METHODS: Margin widths, determined by direct measurement or ocular micrometry, and standardized evaluation of the tumor for nuclear grade, comedonecrosis, and size were performed on 469 specimens of ductal carcinoma in situ from patients who had been treated with breast-conserving surgery with or without postoperative radiation therapy, according to the choice of the patient or her physician. We analyzed the results in relation to margin width and whether the patient received postoperative radiation therapy. RESULTS: The mean (+/-SE) estimated probability of recurrence at eight years was 0.04+/-0.02 among 133 patients whose excised lesions had margin widths of 10 mm or more in every direction. Among these patients there was no benefit from postoperative radiation therapy. There was also no statistically significant benefit from postoperative radiation therapy among patients with margin widths of 1 to <10 mm. In contrast, there was a statistically significant benefit from radiation among patients in whom margin widths were less than 1 mm. CONCLUSIONS: Postoperative radiation therapy did not lower the recurrence rate among patients with ductal carcinoma in situ that was excised with margins of 10 mm or more. Patients in whom the margin width is less than 1 mm can benefit from postoperative radiation therapy.


Asunto(s)
Neoplasias de la Mama/cirugía , Carcinoma in Situ/cirugía , Carcinoma Ductal de Mama/cirugía , Mastectomía Segmentaria , Recurrencia Local de Neoplasia , Neoplasias de la Mama/patología , Neoplasias de la Mama/radioterapia , Carcinoma in Situ/patología , Carcinoma in Situ/radioterapia , Carcinoma Ductal de Mama/patología , Carcinoma Ductal de Mama/radioterapia , Supervivencia sin Enfermedad , Femenino , Humanos , Mastectomía Segmentaria/métodos , Recurrencia Local de Neoplasia/prevención & control , Periodo Posoperatorio , Radioterapia Adyuvante , Estudios Retrospectivos
3.
J Clin Oncol ; 16(4): 1367-73, 1998 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-9552039

RESUMEN

PURPOSE: To detail the outcome, in terms of local recurrence, local invasive recurrence, distant recurrence, and breast cancer mortality for patients previously treated for ductal carcinoma in situ (DCIS). PATIENTS AND METHODS: Clinical, pathologic, and outcome data were collected prospectively for 707 patients with DCIS accrued from 1972 through June 1997. RESULTS: There were 74 local recurrences; 39 were noninvasive (DCIS) and 35 were invasive. Fifty-one percent of patients with invasive recurrences presented with stage 1 disease; the remainder presented with more advanced disease. Invasive local recurrence after mastectomy was a rare event that occurred in 0.8% of patients. Invasive recurrence after breast preservation was more common and occurred in 7.4% of patients. The 8-year probability of breast cancer mortality after breast preservation was 2.1%, a number that is likely to increase with longer follow-up. The 8-year breast cancer-specific mortality and distant-disease probability for the subgroup of 74 patients with locally recurrent disease was 8.8% and 20.8%, respectively. If only the 35 invasive recurrences are considered as events, the 8-year breast cancer-specific mortality and distant-disease probability was 14.4% and 27.1%, respectively. CONCLUSION: Invasive local recurrence after breast-preservation treatment for patients with DCIS is a serious event that converts patients with previous stage 0 disease to patients with disease that ranges from stage I to stage IV. These results, however, indicate that most DCIS patients with local recurrence can be salvaged.


Asunto(s)
Neoplasias de la Mama/patología , Carcinoma in Situ/patología , Carcinoma Ductal de Mama/patología , Recurrencia Local de Neoplasia/mortalidad , Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/radioterapia , Neoplasias de la Mama/cirugía , Carcinoma in Situ/mortalidad , Carcinoma in Situ/radioterapia , Carcinoma in Situ/cirugía , Carcinoma Ductal de Mama/mortalidad , Carcinoma Ductal de Mama/radioterapia , Carcinoma Ductal de Mama/cirugía , Terapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Mastectomía , Invasividad Neoplásica , Recurrencia Local de Neoplasia/patología , Probabilidad , Resultado del Tratamiento
4.
Plast Reconstr Surg ; 98(7): 1216-24, 1996 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-8942907

RESUMEN

Breast conservation therapy, consisting of lumpectomy, axillary node dissection, whole-breast irradiation, and a boost to the tumor bed, is an increasingly popular option for the treatment of breast cancer. Among patients with stage I and stage II disease, breast conservation therapy yields survival rates equivalent to those for mastectomy. The cosmetic results of radiotherapy are usually good, and this approach preserves an intact, sensate breast. Most studies on breast conservation therapy, however, have been performed in nonaugmented patients. Relatively little has been published regarding breast conservation therapy in the presence of silicone implants. Between 1981 and 1994, we treated 33 augmented patients with breast conservation therapy. Among 26 individuals for whom complete follow-up data were available, 17 (65 percent) developed significant capsular contracture on the irradiated side. Thus far 8 patients with radiation-induced contracture have undergone corrective surgery. In our experience, augmented breast cancer patients treated with breast conservation therapy have less satisfactory cosmetic results than nonaugmented women. In addition, mammographic follow-up, critical for identifying local recurrence, may be impaired by the presence of an implant and capsular contracture. On the basis of these considerations, breast conservation therapy may be less than optimal in augmented cancer patients unless explantation is performed before treatment.


Asunto(s)
Implantes de Mama , Neoplasias de la Mama/radioterapia , Mamoplastia , Complicaciones Posoperatorias/radioterapia , Adulto , Anciano , Femenino , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Radioterapia/efectos adversos
6.
Cancer ; 77(11): 2267-74, 1996 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-8635094

RESUMEN

BACKGROUND: There is controversy and confusion regarding therapy for patients with ductal carcinoma in situ (DCIS) of the breast. The Van Nuys Prognostic Index (VNPI) was developed to aid in the complex treatment selection process. METHODS: The VNPI combines three significant predictors of local recurrence: tumor size, margin width, and pathologic classification. Scores of 1 (best) to 3 (worst) were assigned for each of the 3 predictors and then totaled to give an overall VNPI score ranging from 3 to 9. Three hundred thirty-three patients with pure DCIS treated with breast preservation (195 by excision only and 138 by excision plus radiation therapy) were studied with detection of local recurrence as the end point. RESULTS: There was no statistical difference in the 8 year local recurrence free survival in patients with VNPI scores of 3 or 4, regardless of whether or not radiation therapy was used (100% vs. 97%; P = not significant). Patients with VNPI scores of 5, 6, or 7 received a statistically significant 17% local recurrence free survival benefit when treated with radiation therapy (85% vs. 68%; P = 0.017). Patients with scores of 8 or 9, although showing the greatest relative benefit from radiation therapy, experienced local recurrence rates in excess of 60% at 8 years. CONCLUSIONS: DCIS patients with VNPI scores of 3 or 4 can be considered for treatment with excision only. Patients with intermediate scores (5, 6, or 7) show a 17% decrease in local recurrence rates with radiation therapy. Patients with VNPI scores of 8 or 9 exhibit extremely high local recurrence rates, regardless of irradiation, and should be considered for mastectomy.


Asunto(s)
Neoplasias de la Mama/mortalidad , Carcinoma in Situ/mortalidad , Carcinoma Ductal de Mama/mortalidad , Índice de Severidad de la Enfermedad , Neoplasias de la Mama/química , Neoplasias de la Mama/patología , Neoplasias de la Mama/radioterapia , Neoplasias de la Mama/cirugía , Carcinoma in Situ/química , Carcinoma in Situ/patología , Carcinoma Ductal de Mama/química , Carcinoma Ductal de Mama/patología , Carcinoma Ductal de Mama/radioterapia , Carcinoma Ductal de Mama/cirugía , Terapia Combinada , Supervivencia sin Enfermedad , Femenino , Humanos , Tablas de Vida , Mastectomía , Mastectomía Segmentaria , Recurrencia Local de Neoplasia , Pronóstico , Radioterapia Adyuvante , Análisis de Supervivencia
8.
Lancet ; 345(8958): 1154-7, 1995 May 06.
Artículo en Inglés | MEDLINE | ID: mdl-7723550

RESUMEN

We present a new prognostic classification designated the Van Nuys classification for ductal carcinoma-in-situ (DCIS). The classification combines high nuclear grade and comedo-type necrosis to predict clinical recurrence. Three groups of DCIS patients were defined by the presence or absence of high nuclear grade and comedo-type necrosis: 1--non-high-grade DCIS without comedo-type necrosis, 2--non-high-grade DCIS with comedo-type necrosis, 3--high-grade DCIS with or without comedo-type necrosis. There were 31 local recurrences in 238 patients after breast-conservation surgery 3.8% (3/80) in group 1, 11.1% (10/90) in group 2, and 26.5% (18/68) in group 3. The 8-year actuarial disease-free survivals were 93%, 84%, and 61%, respectively (all p < or = 0.05). The Van Nuys classification defines three distinct and easily recognisable groups, each of which has a different likelihood of local recurrence if treated with breast conservation.


Asunto(s)
Neoplasias de la Mama/clasificación , Neoplasias de la Mama/patología , Carcinoma in Situ/clasificación , Carcinoma in Situ/patología , Carcinoma Ductal de Mama/clasificación , Carcinoma Ductal de Mama/patología , Neoplasias Óseas/secundario , Neoplasias de la Mama/terapia , Carcinoma in Situ/secundario , Carcinoma in Situ/terapia , Carcinoma Ductal de Mama/secundario , Carcinoma Ductal de Mama/terapia , Terapia Combinada , Supervivencia sin Enfermedad , Humanos , Mastectomía , Mastectomía Segmentaria , Necrosis , Recurrencia Local de Neoplasia , Pronóstico , Estudios Prospectivos
9.
Cancer ; 73(6): 1673-7, 1994 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-8156495

RESUMEN

BACKGROUND: Infiltrating lobular carcinomas (ILC) represent approximately 10% of all breast cancers. The literature is mixed regarding their prognosis when compared with infiltrating duct carcinomas (IDC). There are few data regarding the treatment of ILC with radiation therapy. METHODS: The clinical, pathologic, laboratory, and survival data of 161 patients with ILC were compared with the data of 1138 patients with IDC. RESULTS: ILCs were larger, more difficult to excise completely, and more difficult to diagnose clinically. All prognostic factors measured were more favorable for ILC. Nodal positivity for ILC was 32%, compared with 37% for IDC (P = 0.22). The 7-year disease-free Kaplan-Meier survival (DFS) was 74% for patients with ILC and 63% for patients with IDC (P < 0.03). The 7-year breast cancer specific survival (BCSS) was 83% for patients with ILC and 77% for patients with IDC (P < 0.04). Selected patients with smaller lesions were treated with excision and radiation therapy. Patients with ILC treated with radiation therapy had a better DFS and BCSS than did patients with IDC treated with radiation therapy. CONCLUSIONS: ILCs often are homogeneous, small cell tumors of low nuclear grade. Their desmoplastic reaction may be absent or less marked than that of IDC, making them more difficult to palpate and to visualize mammographically. Despite this, they can be treated successfully with either mastectomy or excision and radiation therapy.


Asunto(s)
Neoplasias de la Mama/patología , Neoplasias de la Mama/terapia , Carcinoma Ductal de Mama/patología , Carcinoma Ductal de Mama/terapia , Carcinoma Lobular/patología , Carcinoma Lobular/terapia , Factores de Edad , Antineoplásicos/uso terapéutico , Biopsia , Braquiterapia , Protocolos Clínicos , Terapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Escisión del Ganglio Linfático , Ganglios Linfáticos/patología , Mastectomía , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Radioterapia de Alta Energía , Tasa de Supervivencia
10.
Arch Surg ; 127(9): 1038-41; discussion 1041-3, 1992 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-1514905

RESUMEN

Randomized studies of stage I and II breast cancer have shown that breast conservation treatment is equivalent to modified radical mastectomy in regard to local-regional control and survival. Little has been published on breast conservation for patients with large tumors. We analyzed 68 patients with tumors measuring 4 cm or larger (range, 4 to 12 cm) treated with breast-conserving surgery and radiation therapy. The median follow-up was 46 months; the mean tumor size was 5 cm. The 5-year actuarial local-regional recurrence rate was 8.5%, and the overall survival and disease-free survival rates were 76% and 68%, respectively. We conclude that breast conservation treatment may be a reasonable alternative to mastectomy in patients with tumors 4 cm or larger without compromise in local-regional control or survival, while achieving acceptable cosmesis.


Asunto(s)
Neoplasias de la Mama/patología , Neoplasias de la Mama/cirugía , Mama/cirugía , Mama/patología , Mama/efectos de la radiación , Neoplasias de la Mama/radioterapia , Quimioterapia Adyuvante , Estética , Femenino , Estudios de Seguimiento , Humanos , Escisión del Ganglio Linfático , Mastectomía Segmentaria/métodos , Metástasis de la Neoplasia , Recurrencia Local de Neoplasia , Estadificación de Neoplasias , Satisfacción del Paciente , Cuidados Posoperatorios , Dosificación Radioterapéutica , Tasa de Supervivencia , Resultado del Tratamiento
11.
Cancer ; 69(11): 2789-95, 1992 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-1571910

RESUMEN

Earlier literature suggests a high incidence of multicentricity and bilaterality, with an overall poor prognosis, in patients with invasive lobular carcinoma of the breast. Consequently, there is considerable disagreement regarding appropriate local management of this disease. To determine the influence of invasive lobular histologic findings on local tumor control, disease-free survival, and overall survival, the authors reviewed 60 patients with Stage I and II invasive lobular breast carcinoma treated with local tumor excision and radiation therapy between 1981 and 1987 (mean follow-up, 5.5 years; range, 2.5 to 10 years). The 5-year actuarial risk of locoregional recurrence was 5%, with two of three failures occurring in the regional lymphatics. The mean time to locoregional failure was 28 months. The 5-year actuarial disease-free survival (84%) and overall survival (91%) were comparable to those seen in several large series of similarly treated patients with invasive ductal carcinoma. Contralateral breast cancer occurred at a rate of approximately 0.6% per year. This study and a review of the literature suggest that breast conservation, with local resection and radiation therapy, is appropriate therapy for invasive lobular breast cancer.


Asunto(s)
Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/terapia , Carcinoma/terapia , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/patología , Carcinoma/mortalidad , Carcinoma/patología , Femenino , Estudios de Seguimiento , Humanos , Metástasis Linfática , Persona de Mediana Edad , Estadificación de Neoplasias , Neoplasias Primarias Múltiples/diagnóstico por imagen , Neoplasias Primarias Múltiples/epidemiología , Neoplasias Primarias Múltiples/radioterapia , Neoplasias Primarias Múltiples/cirugía , Pronóstico , Radiografía , Dosificación Radioterapéutica , Tasa de Supervivencia
12.
Plast Reconstr Surg ; 89(5): 953-5, 1992 May.
Artículo en Inglés | MEDLINE | ID: mdl-1561266

RESUMEN

This report describes an unusual case in which reduction mammaplasty was performed following radiation therapy for breast cancer. While healing was significantly prolonged (compared with the nonirradiated contralateral breast), the final result was satisfactory from both the functional and the aesthetic standpoint. Women with prior radiation therapy may be considered candidates for reduction mammaplasty. Patients should be warned of the increased risks of wound complications, the likelihood of delayed healing, and the possibility of pigmentation changes in the grafted nipple-areola complex. We elected to transpose the nipple as a full-thickness graft, but consideration also might be given to use of an inferiorly based pedicle flap.


Asunto(s)
Neoplasias de la Mama/radioterapia , Mamoplastia , Neoplasias de la Mama/cirugía , Terapia Combinada , Femenino , Humanos , Mastectomía Segmentaria , Persona de Mediana Edad , Factores de Tiempo
13.
Eur J Cancer ; 28(2-3): 630-4, 1992.
Artículo en Inglés | MEDLINE | ID: mdl-1317201

RESUMEN

From 1979 to 1990, 227 patients with intraductal carcinomas (DCIS) without microinvasion were selectively treated; the least favourable (large lesions with involved biopsy margins) with mastectomy, the most favourable (small lesions with clear margins) with breast preservation. The preservation group was further subdivided into those who received radiation therapy (excision and radiation) and those who did not (excision alone). In the mastectomy group, there were 98 patients (43%) with an average lesional size of 3.3 cm; 41% had multifocal lesions, 15% had multicentric lesions. There has been one local invasive recurrence and no deaths. The 7-year actuarial disease-free survival is 98% with mastectomy. In the excision and radiation group, there were 103 patients (45%) with an average lesional size of 1.4 cm. 10 patients have had local recurrences (5 invasive and 5 noninvasive) one of whom has died. The 7-year actuarial disease-free survival is 84%, a statistically significant difference when excision and radiation is compared with mastectomy (P = 0.038). In the excision alone group, there were 26 patients (11%) with an average lesional size of 1.0 cm. There have been two local recurrences (8%), one of which was invasive and no deaths. The 7-year actuarial disease-free survival is 67%, but only 3 patients have been followed for more than 4 years. A total of 163 axillary node dissections were done; all were negative. Since DCIS without microinvasion rarely metastasizes to axillary lymph nodes, routine dissection should not be performed. Patients in this series with intraductal carcinoma treated with excision and radiation recurred locally at a statistically higher rate than those treated with mastectomy, in spite of the fact that those chosen for excision and radiation had clinically more favourable lesions. 6 of 12 (50%) local recurrences in conservatively treated patients were invasive. There was, however, no significant difference in overall survival in any subgroup regardless of treatment.


Asunto(s)
Neoplasias de la Mama/cirugía , Carcinoma in Situ/cirugía , Carcinoma Intraductal no Infiltrante/cirugía , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/radioterapia , Carcinoma in Situ/radioterapia , Carcinoma Intraductal no Infiltrante/radioterapia , Terapia Combinada , Femenino , Humanos , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Estudios Retrospectivos
14.
Plast Reconstr Surg ; 87(5): 873-8, 1991 May.
Artículo en Inglés | MEDLINE | ID: mdl-2017496

RESUMEN

Breast conservation therapy (wide local excision, axillary lymph node dissection, and whole-breast irradiation) is an increasingly popular alternative to mastectomy for breast cancer patients. A sizable (and growing) number of breast cancers occur in women with prior augmentation mammaplasty. Augmented breast cancer patients are currently being treated with conservation therapy, but no study has investigated complications and cosmetic results of radiation therapy specifically in this group of women. Between 1981 and 1988, we used conservation therapy in 17 augmented breast cancer patients. Fifteen patients were available for follow-up. In 10 (67 percent), significant capsular contracture occurred in the irradiated breast an average of 12 weeks following completion of treatment. Four patients have undergone revisionary surgery to correct symptoms arising from contracture. This poor outcome contradicts the results reported in previously published studies. We conclude that irradiation of the breast for cancer in augmented women results in a high incidence of scar-tissue contracture and poor cosmetic results.


Asunto(s)
Neoplasias de la Mama/radioterapia , Mama/cirugía , Prótesis e Implantes , Siliconas , Adulto , Anciano , Neoplasias de la Mama/cirugía , Neoplasias de la Mama/terapia , Estética , Femenino , Humanos , Persona de Mediana Edad , Pronóstico , Radioterapia/efectos adversos , Estudios Retrospectivos
15.
Arch Surg ; 126(4): 424-8, 1991 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-1848972

RESUMEN

Of 213 consecutive patients with intraductal carcinoma, 109 were selectively treated with mastectomy and 104 with radiation therapy. There were eight local recurrences, seven in patients treated with radiation therapy and one in a patient treated with mastectomy. Histologically, there were 110 comedocarcinomas and 103 noncomedocarcinomas. Seven local recurrences occurred in patients with comedocarcinomas and one in a patient with a noncomedo tumor. Three (38%) of eight local recurrences (all comedo) were invasive. The 5-year actuarial survival for all subgroups was 100%. The median follow-up was 51 months. Intraductal carcinoma is unlikely to metastasize to axillary lymph nodes, and routine dissection is unnecessary. Ductal carcinoma in situ of the comedo variety is more aggressive and more likely to recur than its noncomedo counterpart. We currently view conservative therapy for patients with intraductal comedocarcinoma with caution.


Asunto(s)
Neoplasias de la Mama/radioterapia , Neoplasias de la Mama/cirugía , Carcinoma Intraductal no Infiltrante/radioterapia , Carcinoma Intraductal no Infiltrante/cirugía , Mastectomía Segmentaria , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/patología , Carcinoma Intraductal no Infiltrante/mortalidad , Carcinoma Intraductal no Infiltrante/patología , Femenino , Humanos , Tablas de Vida , Metástasis Linfática , Persona de Mediana Edad , Invasividad Neoplásica , Recurrencia Local de Neoplasia , Estudios Retrospectivos , Tasa de Supervivencia
16.
Cancer ; 66(1): 102-8, 1990 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-2162238

RESUMEN

Two hundred eight cases of intraductal breast carcinoma (DCIS) were selectively treated; 97 with mastectomy, 96 with radiation therapy, and 15 using excisional biopsy only. Mastectomy patients tended to have larger tumors, involved biopsy margins, palpable and often multifocal tumors. Breast preservation patients tended to have smaller, often occult, tumors with clear surgical margins. Before 1983, mastectomy was more common; during and after 1983, breast preservation was more common. Comedocarcinomas were the most frequent tumors. They were the largest, had the highest percentage of microinvasion (20%), and had the highest recurrence rate (8%). Noncomedo DCIS had a recurrence rate of 1%, one of 103 tumors. The recurrence rate for comedocarcinomas treated with radiation therapy was nearly three times higher than for those treated with mastectomy (11% versus 4%). One of 164 (0.6%) axillary lymph node dissections yielded positive nodes. Nine patients have recurred: two in the mastectomy group and seven in the breast conservation group (P less than 0.1). Eight of nine recurrences were the comedo subtype (P less than 0.05). Three patients developed metastatic disease, two of whom have died. Axillary dissection for intraductal carcinoma of the breast is unlikely to yield involved nodes and is not indicated for most cases. It should be reserved for lesions revealing microinvasion. Conservative therapy for comedocarcinoma must be viewed with caution.


Asunto(s)
Neoplasias de la Mama/terapia , Carcinoma Intraductal no Infiltrante/terapia , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/patología , Neoplasias de la Mama/radioterapia , Carcinoma Intraductal no Infiltrante/patología , Carcinoma Intraductal no Infiltrante/radioterapia , Femenino , Humanos , Mastectomía , Persona de Mediana Edad , Factores de Tiempo
17.
Cancer ; 59(10): 1819-24, 1987 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-3030529

RESUMEN

One hundred patients with intraductal breast carcinoma (DCIS) were treated with either mastectomy (49 patients) or radiation therapy (51 patients). All patients underwent axillary lymph node dissection (average number of nodes removed, 16) as part of their treatment. No patient had any positive axillary lymph nodes. There has been one recurrence in each treatment group (median follow-up, 27 months) and no deaths. Intraductal breast carcinoma has little potential for metastasis to axillary lymph nodes.


Asunto(s)
Neoplasias de la Mama/cirugía , Carcinoma Intraductal no Infiltrante/cirugía , Escisión del Ganglio Linfático , Adulto , Anciano , Axila , Braquiterapia , Neoplasias de la Mama/radioterapia , Carcinoma Intraductal no Infiltrante/radioterapia , Terapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Mastectomía/métodos , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Participación del Paciente
18.
Cancer ; 59(4): 715-22, 1987 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-3802031

RESUMEN

Six hundred fifty-three biopsies were performed for clinically occult, mammographically detected breast abnormalities. One hundred forty-seven cancers (22.5%) were found. Eighty-nine of those cancers (60.5%) were noninvasive. None of the in situ lesions had involved axillary lymph nodes. Of the 58 invasive cancers, only six (10.3%) had metastases to axillary nodes. Fifty-four patients (36.7%) were treated by mastectomy while 93 patients (63.3%) were treated conservatively, 20 by biopsy only, and 73 by lumpectomy, axillary node dissection, and radiation therapy. Only four patients (0.7%) had significant complications.


Asunto(s)
Biopsia/métodos , Neoplasias de la Mama/diagnóstico por imagen , Mamografía/métodos , Adulto , Anciano , Neoplasias de la Mama/terapia , Reacciones Falso Negativas , Femenino , Humanos , Mastectomía , Persona de Mediana Edad
19.
Tidsskr Tandlaeger ; (6): 248-9, 1986 Dec.
Artículo en Danés | MEDLINE | ID: mdl-3296309
20.
Int J Radiat Oncol Biol Phys ; 12(9): 1667-71, 1986 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-3759593

RESUMEN

Results in 256 cases of malignant disease treated by multifraction combination hyperthermia-radiation therapy under the supervision of one physician are presented. The overall response rate was 94% including a 62% complete response. Complications specifically ascribed to hyperthermia were minor, and most side effects of combined treatment were radiation dose related. Tumor response was somewhat better for chest wall recurrence (72% CR) and for adenocarcinoma in general (64% CR), but no significant dependence on tumor site or type was found. Most patients were treated with low dose external radiation with hyperthermia given by air cooled microwave applicators or intracavitary antennae operating at 915 or 300 MHz, and some by interstitial microwave antennae plus 192 Ir. Results appeared to be independent of the microwave source employed. Response did depend on radiation dose: complete response rate with 4000 rad was 65%, and with 2000 rad was 42%.


Asunto(s)
Diatermia , Neoplasias/radioterapia , Braquiterapia/efectos adversos , Neoplasias de la Mama/radioterapia , Terapia Combinada , Diatermia/efectos adversos , Femenino , Humanos , Pronóstico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA